Saudi Arabia Intravenous Immunoglobulin Market Size & Outlook
Saudi Arabia intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Saudi Arabia intravenous immunoglobulin market highlights
- The Saudi Arabia intravenous immunoglobulin market generated a revenue of USD 99.1 million in 2024 and is expected to reach USD 157.9 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 8% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Intravenous immunoglobulin market data book summary
| Market revenue in 2024 | USD 99.1 million |
| Market revenue in 2030 | USD 157.9 million |
| Growth rate | 8% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.7% of the global intravenous immunoglobulin market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 59.8 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 21.19% in 2024. Horizon Databook has segmented the Saudi Arabia intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
In Saudi Arabia, the IVIG market is experiencing significant growth, driven by increasing awareness of immunodeficiency diseases and related conditions. With a focus on conditions such as Guillain-Barre Syndrome and Myasthenia Gravis, the demand for IVIG therapies through hospital and specialty pharmacies is on the rise. The Saudi government’s Vision 2030 Health Sector Transformation Program, which includes initiatives to address immunodeficiency diseases, is expected to further support the growth of the IVIG market in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia intravenous immunoglobulin market size, by application, 2018-2030 (US$M)
Saudi Arabia Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
